Pilot studies have noted DYNC1I1 (dynein cytoplasmic 1 intermediate chain 1) was an adverse factor for the prognosis of patients with liver hepatocellular carcinoma, gastric cancer, colon cancer and glioblastoma (Gong L.-B. Here, DYNC1I1 is linked to colonic neoplasm.